BioLineRx Ltd. (BLRX) stock surged by 5.7% at the last trading close while the BLRX stock price continued to rise by 3.24% in the pre-market trading session. BioLineRx Ltd. is an oncology-focused late-stage biopharmaceutical firm. The business strategy of BioLineRx is to in-license novel drugs, improve them across clinical phases, and then collaborate with pharmaceutical firms for further clinical production and/or commercialization.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
What is happening?
BLRX revealed on April 15, 2021, that it had submitted a poster at the AACR Annual Meeting, which will be held on a simulated basis from April 10-15, 2021. The poster, titled “A Multi-Center Phase 2a Trial of the CXCR4 Inhibitor Motixafortide (BL-8040) in Combination with Pembrolizumab and Chemotherapy, in Patients with Metastatic Pancreatic Adenocarcinoma, the COMBAT Study,” contains new analyses from the Company’s Phase 2a COMBAT/KEYNOTE-202 triple combination research of motixafortide in metastatic pancreatic cancer.
In the COMBAT/KEYNOTE-202 trial, patients with advanced pancreatic ductal adenocarcinoma, or PDAC, were given BioLineRx’s lead therapeutic candidate, motixafortide, in conjunction with KEYTRUDA® and chemotherapy.
Official Statements
Dr. Abi Vainstein, Chief Medical Officer of BioLineRx said that Liver metastases are a major factor in patients with metastatic PDAC having a bad prognosis. BLRX is delighted to present this additional review, which improves the findings announced from the COMBAT/KEYNOTE-202 trial in December 2020, since not only were nearly all patients diagnosed with stage 4 disease at the outset, but the overwhelming majority (80%) of the patients still had liver metastases, highlighting the study’s exceedingly challenging patient population. These findings should be replicated in a clinical experiment, and BLRX team is already working hard to determine the program’s next steps with future partnership collaborators.
